All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 2021 American Society of Pediatric Hematology/Oncology (ASPHO) Conference, the Lymphoma Hub spoke with Peter Cole, Rutgers Cancer Institute of New Jersey, New Brunswick, US. We asked, What targeted therapies are showing promise for the treatment of patients with pediatric lymphoma?
What targeted therapies are showing promise for the treatment of patients with pediatric lymphoma?
Cole firstly summarizes trial data for brentuximab vedotin, a CD30-targeting antibody–drug conjugate, and it's potential to replace chemotherapy as frontline treatment. He then describes the CheckMate-744 trial, investigating a combination of nivolumab, a checkpoint inhibitor, with brentuximab vedotin in children with relapsed/refractory Hodgkin lymphoma. He finishes by outlining future trials for these novel agents.
ECHELON-2 trial: response by CD30 expression
Ranjana Advani speaks about how CD30 expression levels in patients with T-cell lymphoma would affect response to brentuximab vedotin plus cyclophosphamide, doxorubicin, & prednisone.
Pierluigi Porcu | ASH 2018 | Updates on T-/NK-cell lymphoma treatment strategies
Pierluigi Porcu from Thomas Jefferson University discusses updates in T-/NK-cell lymphoma treatment strategies.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox